Monday, November 20, 2017 9:25:35 AM
http://philadelphia.citybizlist.com/article/453310/cure-magazine-announces-winners-of-2017-gbm-heroes-awards
CURE Magazine Announces Winners of 2017 GBM Heroes Awards
11/19/17
CRANBURY, N.J.--(BUSINESS WIRE)--CURE® magazine, the nation’s leading consumer digital and print media enterprise focused entirely on patients with cancer, honored Al Musella, D.P.M.; Linda Liau, M.D.; Kay Verble; and Matt Anthony as this year’s winners of its third annual Glioblastoma Multiforme(GBM) Heroes® Awards. The celebration gala took place yesterday at the City View at the Metreon in San Francisco during the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology.
“Each year, we are honored to award these heroes, who have made significant impact in the GBM community. We are proud of their contributions and are pleased to bring these heroes forward to be recognized for their hard work,” said Michael J. Hennessy Jr., president of Michael J. Hennessy Associates, Inc., parent company of CURE® magazine.
Guest speaker Maria Menounos presented an emotional keynote address during the gala. An actress, a writer and a TV host, Menounos has also been a New York Times bestselling author and CEO and co-founder of AfterBuzz TV, and she has delved into professional wrestling. Most important, Menounos is a brain tumor survivor and a caregiver for her mother, who is battling brain cancer.
The honorees of the 2017 GBM Heroes® Award were nominated by patients, healthcare professionals, advocates and peers for their dedication to the field of glioblastoma multiforme. The winners have excelled in providing care for patients, tremendously contributed to research and strongly advocated to advance the scientific research.
The CURE® magazine 2017 GBM Heroes® are:
Al Musella, D.P.M., Musella Foundation
Musella became involved in the GBM community after his sister-in-law and father were diagnosed with glioblastoma multiforme. To better connect the GBM community, he created an online database and support group. He also founded the Brain Tumor Virtual Trial and the Musella Foundation for Brain Tumor Research & Information Inc.
Linda M. Liau, M.D., Ph.D., MBA
Liau is a renowned, board-certified neurosurgeon, professor and chair of the department of neurosurgery at the David Geffen School of Medicine at UCLA. She specializes in intraoperative functional brain mapping and imaging for resection of brain tumors such as gliomas, meningiomas and metastatic tumors. Liau has written more than 150 peer-reviewed research articles and has been recognized as a Top Doctor by U.S. News & World Report, which places her among the top 1 percent in the nation in her specialty.
Kay Verble, executive director, the Sontag Foundation; the Brain Tumor Network
Verble is a longtime supporter of the GBM community. As executive director of the Sontag Foundation, she works closely with early-career researchers and clinicians who have received Sontag grants for brain cancer research, and she created a program of high-touch patient navigation services provided by a multidisciplinary team of nurses and social workers. Additionally, Verble serves as a key player in the success of a brain tumor support group in Northeast Florida.
Matt Anthony, Head for the Cure Foundation
In memory of his brother Chris, who passed away from GBM, Anthony and his family established the Head for the Cure Foundation in 2006. The foundation hosts 5k run/walks in 22 markets, which has raised over $9 million to support the work of the Brain Tumor Trials Collaborative (BTTC). In addition to his role at the Cure Foundation, Anthony also holds board positions with companies including VML Foundation, the BTTC and the MD Anderson Cancer Center Board of Visitors.
The GBM Heroes® Recognition program is sponsored by Novocure, a global oncology company.
About CURE®
CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry leading website, CUREtoday.com; innovative video programs, such as CURE Connections®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers. CURE Media Group is part of the Cranbury, New Jersey-based Michael J. Hennessy Associates, Inc. family of businesses, which includes the acclaimed OncLive® (www.onclive.com) platform of resources for the practicing oncologist. For more information, visit curetoday.com or mjhassoc.com.
About Novocure
Novocure is a global oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. Headquartered in Jersey Isle, U.K., Novocure’s U.S. operations are based in Portsmouth, New Hampshire, and New York City. The company also has offices in Switzerland, Germany, and Japan, as well as a research center in Haifa, Israel.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM